Arrowhead Pharmaceuticals (ARWR) Stock Statistics & Valuation Metrics

Arrowhead Pharmaceuticals has a market cap or net worth of $6.92B. The enterprise value is $11.46B.

Market Cap

$6.92B

Enterprise Value

$11.46B

Arrowhead Pharmaceuticals has 141,254,470 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

141,254,470

Owned by Insiders

3.64%

Owned by Institutions

49.70%

Arrowhead Pharmaceuticals’s return on equity (ROE) is -0.00 and return on invested capital (ROIC) is 4.65%.

Return on Equity (ROE)

-0.00

Return on Assets (ROA)

-0.00

Return on Invested Capital (ROIC)

4.65%

Return on Capital Employed (ROCE)

0.08

Revenue Per Employee

1.17M

Profits Per Employee

-2,293.952

Employee Count

711

Asset Turnover

0.60

Inventory Turnover

0.00

The current PE Ratio of Arrowhead Pharmaceuticals is -22.04. Arrowhead Pharmaceuticals’s PEG ratio is 0.00.

PE Ratio

-22.04

PS Ratio

10.41

PB Ratio

15.20

Price to FCF

-92.83

Price to Operating Cash Flow

-119.84

PEG Ratio

0.00

In the last 12 months, Arrowhead Pharmaceuticals had revenue of 829.45M and earned -1.63M in profits. Earnings per share was -0.01.

Revenue

829.45M

Gross Profit

829.45M

Operating Income

98.35M

Pretax Income

51.53M

Net Income

-1.63M

EBITDA

164.82M

Earnings Per Share (EPS)

-0.01

In the last 12 months, operating cash flow was -59.05M and capital expenditures -16.06M, giving a free cash flow of -75.11M billion.

Operating Cash Flow

-59.05M

Free Cash Flow

-75.11M

Free Cash Flow per Share

-0.52

Arrowhead Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.08%

Earnings Yield

-4.54%

Beta

2.45

52-Week Price Change

18.94%

50-Day Moving Average

66.94

200-Day Moving Average

71.69

Relative Strength Index (RSI)

26.29

Average Volume (3m)

1.89M

Arrowhead Pharmaceuticals upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).

Last Earnings Date

Nov 12, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

―

Arrowhead Pharmaceuticals as a current ratio of 4.86, with Debt / Equity ratio of 78.59%

Current Ratio

4.86

Quick Ratio

4.86

Debt to Market Cap

0.06

Net Debt to EBITDA

0.85

Interest Coverage Ratio

1.10

In the past 12 months, Arrowhead Pharmaceuticals has paid 21.42M in taxes.

Income Tax

21.42M

Effective Tax Rate

0.42

Arrowhead Pharmaceuticals EV to EBITDA ratio is -58.03, with an EV/FCF ratio of -103.28.

EV to Sales

11.59

EV to EBITDA

-58.03

EV to Free Cash Flow

-103.28

EV to Operating Cash Flow

-131.36

Arrowhead Pharmaceuticals has $1.60B in cash and marketable securities with $864.07M in debt, giving a net cash position of $737.89M billion.

Cash & Marketable Securities

$1.60B

Total Debt

$864.07M

Net Cash

$737.89M

Net Cash Per Share

$5.22

Tangible Book Value Per Share

$3.21

Gross margin is 100.00%, with operating margin of -33.82%, and net profit margin of -47.79%.

Gross Margin

100.00%

Operating Margin

-33.82%

Pretax Margin

-37.65%

Net Profit Margin

-47.79%

EBITDA Margin

-19.97%

EBIT Margin

-23.82%

The average price target for Arrowhead Pharmaceuticals is $108.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$108.40

Price Target Upside

119.61% Upside

Analyst Consensus

Strong Buy

Analyst Count

12

Revenue Growth Forecast

16.85%

EPS Growth Forecast

-80.39%

Smart Score

1

AI Score

49